Core Insights - Zealand Pharma has entered into an agreement with DCAI to utilize the Gefion AI supercomputer to enhance drug discovery and support its Metabolic Frontier 2030 strategy [1][2][3] Company Overview - Zealand Pharma A/S is a biotechnology company focused on developing medicines for obesity and metabolic health, leveraging over 25 years of peptide research expertise [5][6] - The company has more than ten drug candidates in clinical development, with two products already on the market and three in late-stage development [6] Partnership with DCAI - The collaboration with DCAI will allow Zealand Pharma to integrate enterprise-scale artificial intelligence into its drug discovery workflows, improving the quality and efficiency of medicine creation [2][4] - Gefion's infrastructure, powered by over 1,500 NVIDIA GPUs and renewable energy, provides scalable computational power for large-scale protein-peptide simulations [3][7] Strategic Goals - Zealand Pharma aims to deliver more than 10 clinical programs and achieve industry-leading cycle times from idea to clinic by 2030 as part of its Metabolic Frontier 2030 strategy [4][7] - The integration of DCAI's AI capabilities is expected to reduce development timelines and contribute to innovative metabolic treatments [4][7]

Press release – No. 1 / 2026 Zealand Pharma to present at the J.P. Morgan Healthcare Conference Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California. Adam Steensberg, President and Chief Executive Officer, will take par ...

Core Viewpoint - Zealand Pharma A/S has reported the total number of shares and voting rights as of December 31, 2025, following a share capital increase due to the exercise of employee warrants [1][2]. Group 1: Share Capital and Voting Rights - As of December 31, 2025, Zealand Pharma has a total of 71,515,045 shares, with a nominal value of DKK 1 each, resulting in a share capital of DKK 71,515,045 and an equal number of voting rights [3]. Group 2: Company Overview - Zealand Pharma A/S is a biotechnology company focused on developing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise and advanced data-driven approaches [4]. - The company has more than ten drug candidates that have entered clinical development, with two products already on the market and three candidates in late-stage development [4]. - Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in Boston, Massachusetts [4].

ConversationAdam Lange My name is Adam Lange. I'm the Head of Investor Relations. And on behalf of the entire Zealand Pharma team, we are very pleased to see so many of you today. Thanks a lot for spending the next few hours with us. Today, it is exactly -- almost exactly 2 years ago since we did our last Capital Markets event, our obesity R&D event in December 2023, where for the first time, at least towards a broader audience of investors and analysts, we really articulated the ambition of Zealand Pharma ...

Core Insights - Zealand Pharma aims to redefine weight management and establish leadership in metabolic health through its Metabolic Frontier 2030 strategy, focusing on innovative solutions for obesity and metabolic diseases [2][4][5] Company Strategy - The company plans to target five product launches and maintain a clinical pipeline of over ten programs by 2030, utilizing its peptide expertise and advanced research capabilities to enhance drug discovery [3][7] - Zealand Pharma will leverage strategic partnerships and advanced computational methods to accelerate drug development and expand its molecule-making toolbox [3][6] Research and Development - A new research site in Boston will integrate over 25 years of peptide expertise with AI-driven drug discovery and advanced automation, aiming to enhance the efficiency of drug development [6][7] - The company anticipates multiple clinical readouts in 2026, including Phase 2 data for petrelintide and Phase 3 data for survodutide [7] Leadership and Vision - The CEO, Adam Steensberg, emphasizes the company's commitment to transforming treatment approaches for obesity and metabolic diseases, moving beyond traditional weight loss methods to support overall well-being [4][5] - Zealand Pharma's strategy is designed to address significant healthcare challenges and foster innovation in metabolic health [5]

Core Insights - Zealand Pharma and OTR Therapeutics have entered a multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases [2][3] - The collaboration aims to leverage Zealand Pharma's expertise in obesity and metabolic health alongside OTR Therapeutics' proprietary R&D platform to create transformative treatment options [3][4] Company Overview - Zealand Pharma is a biotechnology company focused on advancing medicines for obesity and metabolic health, with over 25 years of peptide R&D expertise [7][8] - OTR Therapeutics, launched in March 2025, is dedicated to transforming early-stage innovations into impactful therapies for critical diseases, with a focus on oncology, immunology, inflammation, and cardiometabolic diseases [10] Collaboration Details - The agreement involves co-discovery and co-development of innovative therapies for multiple targets in metabolic diseases, with OTR leading research and preclinical development while Zealand Pharma handles clinical development and commercialization [5][6] - OTR Therapeutics will receive an initial upfront payment of USD 20 million, potentially increasing to USD 30 million, with total consideration up to approximately USD 2.5 billion, primarily from commercial milestones [6][7]

Core Insights - Zealand Pharma A/S is hosting a Capital Markets Day on December 11, 2025, in London, focusing on obesity and metabolism, featuring presentations from management and external experts [1][2]. Company Overview - Zealand Pharma A/S, founded in 1998 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative peptide-based medicines [3]. - The company has advanced more than 10 drug candidates into clinical development, with two already on the market and three in late-stage development [2]. Event Details - The Capital Markets Day will take place from 1:00 PM to 5:30 PM GMT (2:00 PM to 6:30 PM CET) at Goldman Sachs International, London [2]. - Registration is available for both in-person and virtual attendance, and a replay of the webcast will be archived on the company's website [2].

Core Viewpoint - Zealand Pharma A/S is hosting a Capital Markets Day on December 11, 2025, in London, focusing on presentations related to obesity and metabolism [1][2]. Company Overview - Zealand Pharma A/S, founded in 1998 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative peptide-based medicines [3]. - The company has advanced more than 10 drug candidates into clinical development, with two already on the market and three in late-stage development [2]. Event Details - The Capital Markets Day will take place from 1:00 PM to 5:30 PM GMT (2:00 PM to 6:30 PM CET) at Goldman Sachs International, London [2]. - Registration is available for both in-person and virtual attendance, and a replay of the webcast will be archived on the company's website [2].

Core Insights - Zealand Pharma is advancing its clinical programs, particularly with petrelintide and survodutide, and is preparing for a catalyst-rich 2026 with significant data readouts expected [3][8][16] Financial Performance - For the first nine months of 2025, Zealand Pharma reported revenues of DKK 9,146 million, a substantial increase from DKK 54 million in the same period of 2024 [4] - The net operating expenses for the year-to-date were DKK 1,479 million, up from DKK 919 million in 2024, excluding transaction-related costs of DKK 196 million associated with the Roche partnership [4][5] - The operating result for the period was DKK 7,666 million, compared to a loss of DKK 873 million in the previous year [4] Clinical Developments - The company achieved a key milestone in the petrelintide Phase 2 ZUPREME-1 trial, with the last participant completing the 28-week primary endpoint visit, paving the way for topline data in H1 2026 [6][8] - Survodutide is approaching Phase 3 data in H1 2026, following the completion of the 76-week SYNCHRONIZETM-1 trial [8] - Zealand Pharma is also preparing to report topline data from the first-in-human trial of ZP9830 in the first half of 2026 [13] Strategic Focus - The company is focusing on its research strategy to lead innovation in obesity treatments, with plans to initiate several Phase 2 and Phase 3 trials in 2026 [3][16] - Development of dapiglutide has been paused to concentrate resources on programs with higher potential for clinical differentiation [15][17] Upcoming Events - Zealand Pharma will host a Capital Markets Day on December 11, 2025, to discuss upcoming data readouts and its research strategy [16][19]

Core Insights - Alvotech reported a quarterly loss of $0.02 per share, which was better than the Zacks Consensus Estimate of a loss of $0.05, but a decline from earnings of $0.19 per share a year ago, resulting in an earnings surprise of -140.00% [1] - The company generated revenues of $113.86 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 11.6%, but showing an increase from $102.99 million in the same quarter last year [2] - Alvotech shares have decreased by approximately 57.8% year-to-date, contrasting with a 16.4% gain in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.03, with expected revenues of $159.54 million, and for the current fiscal year, the estimate is $0.07 on revenues of $576.57 million [7] - The trend of estimate revisions for Alvotech was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Alvotech belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Zealand Pharma A/S, is expected to report a quarterly loss of $1.23 per share, reflecting a year-over-year change of -119.6%, with revenues anticipated to be $4.66 million, a significant increase of 616.2% from the previous year [9][10]